Equity | India |

# ANUPAM RASAYAN INDIA LIMITED



Note

## Recommendation: SUBSCRIBE

## March 9,2021

Details of the Issue	
Price Band	₹ 553- ₹ 555
Issue Size (OFS)	₹ 760 Cr
Opening Date	Mar 12, 2021
Closing Date	Mar 16, 2021
Face Value	₹10
Bid Lot	27
Listing on	BSE, NSE

### **Objects of the Issue**

To make prepayment/repayment of company's indebtedness including accrued interest. To meet general corporate purposes.

### Lead Managers

Ambit Private Limited Axis Capital Limited IIFL Holdings Limited JM Financial Consultants Private Limited

#### Registrar

**KFintech Private Limited** 

Investment Details	
No. of shares at cut-off	351
Max. Amount to be paid	₹ 1,94,805

Source: RHP, GEPL Capital Research

## **Company Background**

Anupam Rasayan is one of the leading companies engaged in the custom synthesis and manufacturing of specialty chemicals in India (Source: F&S Report).

**Business operation** - custom synthesis and manufacturing of life science related specialty chemicals and other specialty chemicals, which involve multi-step synthesis and complex technologies, for a diverse base of Indian and global customers.

Manufactures 36 products as on September 30, 2020. It has six multi-purpose manufacturing facilities in Gujarat, India, with four facilities located at Sachin and two located at Jhagadia and an aggregate installed capacity of 23,438 MT.

### **Business Verticals** -

(i) life science related specialty chemicals comprising products related to agrochemicals, personal care and pharmaceuticals (~95% of revenue)

(ii) other specialty chemicals, comprising specialty pigment and dyes, and polymer additives. (~5% of revenues)

Key Clients - Syngenta Asia Pacific Pte. Ltd., Sumitomo Chemical Company Limited and UPL Limited

Promoters - Mr. Anand S Desai, Dr. Kiran C Patel, Ms. Mona A Desai, KPI LLC and RIRCPL.

### Strengths & Strategies

# Strong and long-term relationships with diversified customers across geographies with significant entry barriers

According to the F&S Report, the custom synthesis and manufacturing industry presents significant entry barriers, including customer validation and approvals, expectation from customers for process innovation and cost reduction, high quality standards and stringent specifications.

# Core focus on process innovation through consistent R&D, value engineering and complex chemistries

The company has a dedicated in-house R&D facility and a pilot plant located at Sachin Unit - 6, which is equipped with laboratories engaged in process development, process innovation, new chemical screening and engineering. It is also one of the companies in manufacturing products using continuous and flow chemistry technology on a commercial scale in India.

### Diversified and customized product portfolio with a strong supply chain

As a result of backward integration, the dependence on imported raw materials as a percentage of total raw materials purchases has decreased from 26.01% in Fiscal 2018 to 25.95% in Fiscal 2019 and further to 22.44% in Fiscal 2020.

## **Diversification of product portfolio**

The R&D team is focused on building knowledge-based value added products, new innovative processes, scaling up the capacity of existing products while lowering the cost of production and improving the existing design parameters to increase the yields and thus the overall product quality.

The company also remains focused on expanding their chemistry expertise and entering into new value chains by adding new reaction capabilities at manufacturing facilities.



### Valuation & Recommendation

The company has strong and long-term relationships with diversified customers across geographies with significant entry barriers and a focus on complex molecules in the early stage of their lifecycle and high growth potential with applications in the life science domain.

Favorable industry dynamics such as India accounting for approximately 1% to 2% of the global exportable specialty chemicals, indicating a large scope of improvement and widespread opportunity. The Government of India's 'Make in India' campaign is also expected to act as a stimulus to the emergence of India as a manufacturing hub for the chemicals industry.

Future growth can be expected to come from expanding the chemistry expertise and entering new value chains offering higher value addition, and thus generating higher margins and increasing profitability.

The proceeds will be used to bring down debt which will help improve financial leverage and improve margins. The offer is priced at a 6x P/B as on September 2020.

We recommend a SUBSCRIBE rating to the issue.

### **Financial Snapshot**

Particulars	H1FY20	H1FY19	FY20	FY19	FY18
Share capital	517.70	500.00	500.00	500.00	500.00
Net worth	6,635.83	5,557.92	5,937.23	5,071.08	4,576.37
Total revenue	3,735.99	2,375.73	5,393.87	5,209.61	3,491.82
РАТ	264.83	217.39	529.75	492.48	413.07
EPS	3.39	2.91	6.94	6.60	6.59
NAV	83.06	71.78	76.00	67.95	61.32
Total borrowings	8,615.82	7,208.14	8,180.19	6,697.49	4,348.97

(In ₹ million except per share data) (6M data not annualized) Source: RHP, GEPL Capital Research



GEPL CAPITAL Pvt Ltd (formerly known as Gupta Equities Pvt. Ltd.) Head Office: D-21/22 Dhanraj mahal, CSM Marg, Colaba, Mumbai 400001 Reg. Office : 922-C, P.J. Towers, Dalal Street, Fort, Mumbai 400001

### Associate Analyst - Gaurav Hinduja

#### Disclaimer:

This report has been prepared by GEPL Capital Private Limited ("GEPL Capital "). GEPL Capital is regulated by the Securities and Exchange Board of India. This report does not constitute a prospectus, offering circular or offering memorandum and is not an offer or invitation to buy or sell any securities, nor shall part, or all, of this presentation form the basis of, or be relied on in connection with, any contract or investment decision in relation to any securities. This report is for distribution only under such circumstances as may be permitted by applicable law. Nothing in this report constitutes a representation that any investment strategy, recommendation or any other content contained herein is suitable or appropriate to a recipient's individual circumstances or otherwise constitutes a personal recommendation. All investments involve risks and investors should exercise prudence in making their investment decisions. The report should not be regarded by the recipients as a substitute for the exercise of their own judgment. Any opinions expressed in this report to change without notice and may differ or be contrary to opinions expressed by other business areas or groups of GEPL Capital as a result of using different assumptions and criteria. GEPL Capital is under no obligation to update or keep current the information contained herein. The securities described herein may not be eligible for sale in all jurisdictions or to certain categories of investors. Options, and trading in these instruments is considered risky. Past performance is not necessarily indicative of future results. Foreign currency rates of exchange may adversely affect the value, price or income of any security or related instrument mentioned in this report.

Any prices stated in this report are for information purposes only and do not represent valuations for individual securities or other instruments. There is no representation that any transaction can or could have been effected at those prices and any prices do not necessarily reflect GEPL Capital's internal books and records or theoretical model-based valuations and may be based on certain assumptions. Different assumptions, by GEPL Capital or any other source may yield substantially different results. GEPL Capital makes no representation or warranty, express or implied, as to, and does not accept any responsibility or liability with respect to, the fairness, accuracy, completeness or correctness of any information or opinions contained herein. Further, GEPL Capital assumes no responsibility to publicly amend, modify or revise any forward-looking statements, on the basis of any subsequent development, information or events, or otherwise. Neither GEPL Capital nor any of its affiliates, directors, employees or agents accepts any liability for any loss or damage arising out of the use of all or any part of this report. In no event shall GEPL capital be liable for any direct, special indirect or consequential damages, or any other damages of any kind, including but not limited to negligence), or otherwise, arising out of or in any way connected with the use of this report. The materials contained in, or accessed through, this report.

GEPL Capital and its affiliates and/or their officers, directors and employees may have similar or an opposite positions in any securities mentioned in this document (or in any related investment) and may from time to time add to or dispose of any such securities (or investment). The disclosures contained in the reports produced by GEPL Capital shall be strictly governed by and construed in accordance with Indian law. GEPL Capital specifically prohibits the redistribution of this material in whole or in part without the written permission of GEPL Capital and GEPL Capital accepts no liability whatsoever for the actions of third parties in this regard.

